Merck Serono Takes Leading Role in Fertility Technologies Signing a Global Collaboration Agreement with Genea Biomedx
Merck announced the global collaboration agreement with the fertility technologies expert Genea Biomedx, an Australian company, dedicated to advancing fertility science and helping couples create families. With this partnership, Merck Serono receives global marketing and commercialization rights to Genea Biomedx’s product portfolio.
“As a pioneer in reproductive health, we are continuously seeking to extend our product portfolio to bring innovative science and services to the fertility community,” explained Belén Garijo, Member of the Executive Board of Merck and CEO Healthcare. “There is significant need for improved technologies in fertility treatment, since the majority of issues in ART are beyond drug therapy. The key priority of our Fertility Technologies unit at Merck Serono is to advance our fertility portfolio beyond drugs and to enable innovation in technologies and services. Entering a global partnership with Genea will allow Merck to introduce innovative technologies in the ART market, further aiming to improve outcomes throughout the in vitro fertilization process. Merck Serono is dedicated to help patients realize their dream of creating a family.”
The collaboration is effective from May 1, 2015. Financial details of the agreement are not being disclosed.
Other news from the department business & finance
